Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Co-mutation signatures are age-dependent and impact the prognosis in <i>NPM1</i>-mutated acute myeloid leukemia: a PETHEMA multicenter study.

Haematologica·2026
Same author

<i>GLI1</i>-Altered neoplasms: From molecular alterations to morphologic and phenotypic features with formal recognition in the upcoming WHO Classification of soft tissue tumors.

Histology and histopathology·2026
Same author

Targeting DNA interstrand crosslinks repair with synthetic lethality in High-Grade B-Cell Lymphoma.

Leukemia·2026
Same author

Contribution of Countries and International Collaboration in Clinical Pharmacology Research. A Cross-Sectional Bibliometric Study of Six Top Ranked Specialty Society Journals.

Basic & clinical pharmacology & toxicology·2026
Same author

Quizartinib in Combination With FLAG-IDA for Relapsed or Refractory Acute Myeloid Leukemia (FLAG-QUIDA): A PETHEMA Phase I-II Trial.

American journal of hematology·2026
Same author

Mutational dynamics in patients with del(5q) MDS treated with lenalidomide prior to transfusion dependency-Molecular results from the Sintrarev clinical trial.

HemaSphere·2026

Related Experiment Video

Updated: Aug 30, 2025

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.0K

An integrated prognostic model for diffuse large B-cell lymphoma treated with immunochemotherapy.

Marta Rodríguez1,2, Ruth Alonso-Alonso1,2, Ismael Fernández-Miranda3

  • 1Pathology Department IIS Hospital Universitario Fundación Jiménez Díaz Madrid Spain.

Ejhaem
|September 2, 2022
PubMed
Summary

A new risk score combining clinical and biological factors improves prognostication for Diffuse Large B-cell Lymphoma (DLBCL) patients treated with R-CHOP immunochemotherapy. This tool enhances survival prediction across diverse patient groups.

Keywords:
DLBCLdiffuse large B‐cell lymphomagene expressionimmunochemotherapyprognosis

More Related Videos

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.4K
Constructing and Visualizing Models using Mime-based Machine-learning Framework
06:19

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Published on: July 22, 2025

464

Related Experiment Videos

Last Updated: Aug 30, 2025

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.0K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.4K
Constructing and Visualizing Models using Mime-based Machine-learning Framework
06:19

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Published on: July 22, 2025

464

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Diffuse Large B-cell Lymphoma (DLBCL) exhibits significant heterogeneity despite uniform R-CHOP treatment.
  • Predictive biomarkers are crucial for refining DLBCL patient stratification and treatment strategies.

Purpose of the Study:

  • To develop and validate a novel risk score integrating clinical and molecular data for DLBCL prognostication.
  • To improve prediction of R-CHOP treatment response and survival outcomes in DLBCL.

Main Methods:

  • Utilized a NanoString platform to analyze gene expression in 197 DLBCL cases.
  • Developed a risk score combining International Prognostic Index, cell of origin, and MYC/BCL2 double expression.
  • Validated the scoring system in an independent cohort of 166 DLBCL patients.

Main Results:

  • The developed risk score significantly stratified DLBCL patients into three groups with distinct overall and progression-free survival.
  • Hazard ratios for overall survival ranged from 0.15 to 5.49, and for progression-free survival from 0.17 to 5.04.
  • The scoring system demonstrated applicability across different age groups and disease stages.

Conclusions:

  • A combined clinical-biological risk score offers improved prognostic accuracy for DLBCL.
  • This model facilitates the integration of biological variables into clinical decision-making for DLBCL.
  • The validated risk score can aid in personalizing treatment strategies for DLBCL patients.